Premature ventricular contraction prevention

Jump to navigation Jump to search

Premature ventricular contraction Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Premature Ventricular Contraction from other Disorders

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Premature ventricular contraction prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Premature ventricular contraction prevention

CDC onPremature ventricular contraction prevention

Premature ventricular contraction prevention in the news

Blogs on Premature ventricular contraction prevention

to Hospitals Treating Premature ventricular contraction prevention

Risk calculators and risk factors for Premature ventricular contraction prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]

Overview

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include:

  • [Strategy 1]
  • [Strategy 2]
  • [Strategy 3]

Recommendations for Secondary Prevention of SCD in Patients With Ischemic Heart Disease

Class I
1. In patients with ischemic heart disease, who either survive SCA due to VT/VF or experience hemodynamically unstable VT (Level of Evidence: B-R) or stable sustained VT (Level of Evidence: B-NR) not due to reversible causes, an ICD is recommended if meaningful survival greater than 1 year is expected.

2. A transvenous ICD provides intermediate value in the secondary prevention of SCD particularly when the patient’s risk of death due to a VA is deemed high and the risk of nonarrhythmic death (either cardiac or noncardiac) is deemed low based on the patient’s burden of comorbidities and functional status (Level of Evidence: B-R).

3. In patients with ischemic heart disease and unexplained syncope who have inducible sustained monomorphic VT on electrophysiological study, an ICD is recommended if meaningful survival of greater than 1 year is expected (Level of Evidence: B-NR).


References

Template:WH Template:WS